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Background: 
 
Genome-wide association studies have identified multiple genetic variants 
associated with prostate cancer (PrCa) risk which explain a substantial 
proportion of familial relative risk. These variants can be used to stratify 
individuals by their risk of PrCa. 
 
Methods: 
 
We genotyped 25 PrCa susceptibility loci in 40,414 individuals and derived a 
polygenic risk score (PRS). We estimated empirical Odds Ratios for PrCa 
associated with different risk strata defined by PRS and derived age-specific 
absolute risks of developing PrCa by PRS stratum and family history.  
 
Results: 
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The PrCa risk for men in the top 1% of the PRS distribution was 30.6 (95% CI 
16.4-57.3) fold compared with men in the bottom 1%, and 4.2 (95% CI 3.2-5.5) 
fold compared with the median risk. The absolute risk of PrCa by age 85 was 
65.8% for a man with family history in the top 1% of the PRS distribution, 
compared with 3.7% for a man in the bottom 1%. The PRS was only weakly 
correlated with serum PSA level (correlation=0.09). 
 
Conclusions: 
 
Risk profiling can identify men at substantially increased or reduced risk of 
PrCa. The effect size, measured by OR per unit PRS, was higher in men at 
younger ages and in men with family history of PrCa. Incorporating additional 
newly identified loci into a PRS should improve the predictive value of risk 
profiles.  
 
Impact: 
 
We demonstrate that the risk profiling based on SNPs can identify men at 
substantially increased or reduced risk that could have useful implications for 
targeted prevention and screening programs.  
 
Introduction 
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Genome-wide association studies (GWAS) have identified multiple common genetic 
variants associated with prostate cancer (PrCa) risk. The risks associated with such 
variants are generally modest, but in combination their effects may be substantial, 
and may provide the basis of targeted prevention (1). However, since the risks 
associated with these variants are modest, large studies are required to estimate 
their risks precisely. To facilitate this estimation, we genotyped 25 PrCa susceptibility 
SNPs in studies from the PRACTICAL consortium. PRACTICAL is an international 
PrCa consortium that includes more than 78 studies, including men of European, 
Asian or African ancestry, and has a combined dataset of over 130,000 samples 
(http://practical.ccge.medschl.cam.ac.uk/). In the current analysis, we utilised data 
from 31,833 cases and controls from 24 studies in PRACTICAL and 8,581 samples 
from replication stage of a GWAS (“GWAS stage 3”). Sixteen out of the twenty five 
SNPs that we used in this study were identified through studies that included PRACTICAL 
(2-4) and nine SNPs were identified by other GWAS (5-10). 
 
Materials and Methods 
 
Samples 
The current analysis was restricted to individuals of European ancestry, based on 
self-reported ethnicity, and thus we excluded samples with non-European ancestry. 
Data were contributed from 25 studies in PRACTICAL and GWAS stage 3. Twenty 
five SNPs were genotyped specifically for this analysis in 31,833 cases and controls 
in PRACTICAL phase III, unless the genotype data were already available. We also 
included four studies from the GWAS stage 3 conducted in the United Kingdom and 
Australia, comprising a further 8,581 cases and controls (11). In this replication 
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stage 1,536 SNPs were genotyped, including the 25 susceptibility SNPs analysed 
here. These two datasets were combined to give a total of 40,414 samples (20,288 
cases and 20,126 controls). Three studies (MCCS, PFCS and UKGPCS) that were 
included in the GWAS stage 3 also contributed genotyping of additional samples for 
PRACTICAL phase III (Table1, Supplementary Table 1 and Supplementary Notes). 
Studies provided a minimum core dataset that included disease status, age at 
diagnosis/observation and ethnicity. Twenty two studies provided data on family 
history and eighteen studies provided data on Gleason score. 
 
Where studied included more than one individual from the same family, only the 
index case was included, so that the analyses were based on unrelated men. For 
analyses of the polygenic risk score (PRS) we also excluded 5 studies (MAYO, 
PCFS, TASPRAC, ULM and UTAH) that oversampled cases with family history of 
PrCa. This reduced the total number of samples to 34,986 (16,643 cases and 
18,343 controls). All studies were approved by the relevant ethics committees. 
 
Eighty Nine percent (31,150) of the samples had information on age at diagnosis 
(interview/blood draw for controls). The mean age at diagnosis for the cases was 64 
years, slightly higher than the mean age at interview/blood draw for the controls (58 
years; Supplementary Table 2a). Family history information was available for 21,209 
(60.6%) samples and among samples with family history information, 10.7% of 
controls and 18.2% of cases had a family history of PrCa. Before excluding studies 
with oversampled familial cases, these percentages were 12.9% and 22.6% 
respectively (Supplementary Table 2a and b).  
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Genotyping 
 
Genotyping was performed in two experiments; these were subject to separate QC 
procedures appropriate to the platforms used, before the data were combined for 
statistical analysis. In PRACTICAL phase III, genotyping of samples from 2 studies 
was performed by Sequenom, while 22 study sites performed the 5’exonuclease 
assay (Taqman™) using the ABI Prism 7900HT sequence detection system 
according to the manufacturer’s instructions. Primers and probes were supplied 
directly by Applied Biosystems as Assays-By-Design™. Assays at all sites included 
at least four negative controls and 2-5% duplicates on each 384-well plate. Quality 
control guidelines were followed by all the participating groups as previously 
described (4). In addition, all sites also genotyped 16 CEPH samples.  We excluded 
individuals that were not typed for at least 80% of the SNPs attempted. Data on a 
given SNP for a given site were also excluded if they failed any of the following QC 
criteria: SNP call rate >95%, no deviation from Hardy-Weinberg equilibrium in 
controls at P<.00001; <2% discordance between genotypes in duplicate samples 
and in the CEPH control samples. Cluster plots for SNPs that were close to failing 
any of the QC criteria were re-examined centrally. 
 
GWAS Stage 3 genotypes were generated using an Illumina Golden Gate Assay. All 
SNPs for this analysis passed the QC filters used for this experiment:  call rate>95%, 
a minor allele frequency in controls of >1%, or genotype frequency in controls 
consistent with Hardy-Weinberg equilibrium at p<0.00001. Duplicate concordance 
was 99.99% (11). 
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Statistical methods 
 
We used combined data across all studies for the analysis. We assessed the 
association between each SNP and PrCa using a 1-degree-of-freedom Cochran-
Armitage trend test, stratified by studies. Odds ratios (OR) and 95% confidence 
intervals (95% CI) associated with each genotype and cancer risk, and genotypes 
for pairs of SNPs, were estimated using unconditional logistic regression, stratified 
by study as a covariate. Both per-allele ORs, and genotype-specific ORs, were 
estimated. Heterogeneity in the OR estimates among studies was evaluated using a 
likelihood ratio test, by comparing with a model in which separate ORs were 
estimated for each study. 
 
Modification of the ORs by disease aggressiveness and family history was assessed 
by using both family history (Yes vs. No) and Gleason score (<8 vs. ≥8) as binary 
variables. A test for association between SNP genotype at a locus and Gleason 
score as an ordinal variable was also performed, using polytomous regression. 
Modification of the ORs by age was assessed using a case-only analysis, assessing 
the association between age and SNP genotype in the cases using polytomous 
regression. The associations between SNP genotypes and PSA level were 
assessed using linear regression, after log-transformation of PSA level to correct for 
skewness. 
 
Contribution to Familial Risk  
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The contribution of the known SNPs to the familial risk of PrCa, under a multiplicative 
model, was computed using the formula: 
 
where  is the observed familial risk to first degree relatives of PrCa cases, assumed to 
be 2 (12), and  is the familial relative risk due to locus k, given by: 
 
where is the frequency of the risk allele for locus k,  and is the estimated 
per-allele odds ratio (13). 
 
To evaluate evidence for interactions between pairs of SNPs, we used a likelihood 
ratio test and evaluated the evidence for departures from a multiplicative model, by 
comparing models with and a model without the interaction term for each pair of 
SNPs. The interaction term was the product of the allele doses for the two SNPs, 
hence leading to a 1 degree of freedom test for an interaction. Based on the 
assumption of a log-additive model, we constructed a PRS from the summed 
genotypes weighted by the estimated per-allele log-odds ratios for each SNP, as 
estimated by logistic regression as above. Thus for each individual j we derived: 
Where: 
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ijg : Allele dose at SNP i (0, 1, 2) for individual j 
i : Per-allele log-odds ratio of SNP i   
 
The missing genotypes for an individual were replaced with the mean genotype of 
each SNP separately for cases and controls. A sensitivity analysis, in which 
analyses were based on samples with complete genotype data, gave very similar 
results (data not shown). We then standardised the PRS by dividing by the overall 
standard deviation of PRS in the controls.  
 
The risk of PrCa was estimated for the percentiles of the distribution of the PRS; 
<1%, 1-10%, 10-25%, 25-75% (defined here as “median risk”), 75-90%, 90-99%, 
>99%; and per standard deviation when fitted as a continuous covariate. We 
evaluated the fit of the combined risk score to a log-linear model by comparing the 
model with the PRS fit as a continuous covariate with a model in which separate 
parameters were estimated for percentiles of risk adjusted for age at diagnosis and 
family history, using a likelihood ratio test. 
 
We used a likelihood ratio test to evaluate the evidence for interaction between PRS 
and age at diagnosis/observation, PRS and family history and also family history and 
age at diagnosis/observation by comparing models with and a model without an 
interaction term. Effect sizes by family history were compared using a case-only 
analysis. Analyses were performed using Stata 13. 
 
The relative risk estimates were used to obtain estimates of the absolute risk of PrCa 
by PRS category and family history. Since we observed evidence for an interaction 
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between PRS and age, we used both models with and without PRS x age interaction 
term. Absolute risks were constrained such that the age-specific incidences, 
averaged over all categories of PRS and family history, were consistent with the age-
specific incidences of PrCa for the UK population for 2012 (http://ci5.iarc.fr/CI5plus) 
(14). The model was adjusted for age at diagnosis (age <55, 55-59, 60-64, 65-70 
and 70+). The procedure for deriving the age-specific incidences for each SNP 
profile category has been performed following the procedure explained by Antoniou 
et al. (15, 16), but adjusted to allow for competing causes of death. 
 
For this purpose, we categorised PRS into seven risk groups (k=risk group 1 to 7), 
based on the percentile in the controls: <1%, 1-10%, 10-25%, 25-75%, 75-90%, 90-
99% and >99%. We could not find any evidence for an interaction between PRS and 
family history of PrCa (P-value=0.49) and assumed that family history and PRS are 
independently predictive of PrCa risk. Under this model, the PrCa incidence at 
age t for an individual in risk group k and family history group h (h=1 with family 
history, h=0 no family history) was assumed to follow a model of the form:
)exp()()( 0
h
k
h
k tt   where  is  the baseline PrCa incidence and )exp(
h
k  is the 
risk ratio in the risk group k and family history group h, relative to the baseline 
category (h=0, k=1), approximated by the odds ratio estimates from the logistic 
regression analysis. To obtain the baseline incidence, , we constrained the PrCa 
incidence averaged all risk groups to agree with the population age-specific PrCa 
incidences (the incidence of PrCa at age t per 100,000 individuals in the UK 
(14)). The baseline incidence can be obtained for each age by: 
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Here is the probability of having no family history in the population (89.26% in the 
controls in this dataset) and 𝑝1 = 1 − 𝑝0 is the probability of having family history in 
the population (10.74% in the controls in this dataset). is frequency of the SNP 
profile risk group k ( =0.01, =0.09, =0.15, =0.5, =0.15, =0.09, 
=0.01) and  is the probability of surviving PrCa by age (t) in the risk group k for 
samples in the family history group h, which can be derived from incidence rates 
for ages <t using the formula ))1(exp()(
0
  ttS
t
h
k
h
k  . Since definition  
for all k and h, it was possible to solve the above equation recursively, starting at 
age t=0, to obtain the baseline incidences and hence the age-specific PrCa 
incidences at age (t), , for each group. We then computed the absolute risk by 
age t, adjusting for mortality from other causes, for each risk group, using the 
formula:     
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cc   is the probability of not dying from another cause of 
death by age t, based on the age-specific mortality rates )(tc . The age-specific 
mortality rates, )(tc , was estimated by using all causes incidences of death per 
100,000 individuals for England and Wales (http://www.ons.gov.uk/ons/index.html) 
and the PrCa death incidence per 100,000 individuals in UK in year 2012 (14). 
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Results 
 
All 25 SNPs showed evidence of association with PrCa (P=0.02 to P=1.4x10-46), with 
effect sizes that were consistent with previous reports. The largest per-allele OR 
estimate was 1.56 (95% CI 1.44-1.68) for rs16901979 on 8q24 (Table 2). For each 
of the 24 autosomal SNPs, the effect size was larger for rare homozygotes than for 
heterozygotes, and the estimates were consistent with a multiplicative (log-additive) 
model. There was no evidence for heterogeneity among studies (Table 2).  
 
Gleason score was available for 15,107 (74.5%) of the cases used in the analyses; 
of these, 2,139 had a score of 8+ and 12,968 had a score less than 8. One SNP, 
rs1447295, on chromosome 8, showed a larger effect size with increasing grade 
(P=0.001), while four SNPs (rs17021918, rs1512268, rs7127900 and rs2735839) 
showed a larger effect sizes with decreasing grade (P<0.02; Supplementary Table 
3). 
 
Thirteen of the SNPs (rs1465618, rs7679673, rs10486567, rs1447295, rs6983267, 
rs16901979, rs10993994, rs7931342, rs7127900, rs4430796, rs11649743, 
rs1859962 and rs5759167) showed a higher per-allele OR for cases with a PrCa 
family history than those without (P<0.05), while no SNPs showed an effect in the 
opposite direction consistent with the predictions under a polygenic model (17) 
(Supplementary Table 3). 
 
Data on serum PSA level were available for 3,922 controls from 6 studies. Six SNPs 
(rs1447295, rs6983267, rs1512268, rs10993994, rs7127900 and rs2735839) 
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showed association with PSA concentration levels significant at P-value < 0.03. 
rs1447295 showed an association with PSA in the opposite direction of the PrCa risk 
association but the rest of five SNPs showed an association with PSA in the same 
direction of the PrCa risk association (Supplementary Table 4).  
 
Seven SNPs (rs1465618, rs12621278, rs10993994, rs7127900, rs1859962, 
rs2735839 and rs5945619) showed an evidence for a trend in the per-allele ORs 
with age; in each case the effect size was larger for cases diagnosed at younger 
ages (Supplementary Table 5). 
  
The combined effect of all pairs of SNPs was evaluated through a logistic regression 
model that included each pair of SNPs and an interaction term.  The interaction term 
was significant at P-value <0.05 level for 29 pairs (out of 300 possible pairs) 
compared with 15 expected by chance, and significant at the P-value <0.01 level for 
12 pairs compared with 3 expected by chance. However, no pair was significant at 
the P-value <0.05 level after a bonferroni correction for the number of tests (nominal 
significance P-value=1.6x10-4, Supplementary Table 6).  
 
Under the assumption that these 25 SNPs combined approximately multiplicatively 
to alter the risk of PrCa, we constructed a PRS for 16,643 cases and 18,343 controls 
based on the estimated per-allele ORs of 25 SNPs, standardised by the standard 
deviation in controls. The standardised PRS had a mean=0.651 (range -3.81-5.36; 
SD=0.98) in cases and mean=0.104 (range -4.05-4.15; SD=1) in controls.  The 
standardised PRS was strongly associated with disease risk (OR per unit PRS 
=1.74, 95%CI 1.70-1.78). The OR per unit increase of the standardised PRS 
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declined with age from 1.76 (95% CI 1.62-1.92) in cases diagnosed at age less than 
55 to 1.48 (95% CI 1.37-1.60) in cases diagnosed at age 70+ (P-value= 2.6x10-4, 
Supplementary Table 5). 
 
The OR per unit increase of PRS was larger for men with PrCa family history (1.79 
Vs 1.70; P-value= 1.8x10-4, Supplementary Table 3). We found no evidence of an 
interaction between PRS and family history (P-value=0.49) or between age at 
diagnosis and family history (P-value=0.11) but there was some evidence for an 
interaction between PRS and age at diagnosis (P-value=0.003). 
 
There was no evidence of a difference in the OR per unit PRS according to Gleason 
Score (OR=1.75, GS<8 Vs OR=1.65, GS 8+) after adjusting for age at diagnosis and 
family history (P=0.37; Supplementary Table 3). The correlation between PSA and 
the PRS was weak, both in controls (correlation=0.09) and in cases (correlation 
=0.02).  
 
When PRS was categorised by percentile, the top 1% of the population had an 
estimated OR of 30.6 (16.4-57.3) compared with the bottom 1% of the population, 
and an OR of 4.2 (95%CI 3.2-5.5) compared with the median population risk 
(defined as the 25-75% risk group). The bottom 1% of the population had an 
estimated OR of 0.14 (95% CI 0.08-0.24) compared with the median risk (Table 3). 
After allowing for an interaction between PRS and age, the OR for the top 1% of the 
population, relative to the median risk group, decreased from 5.6, for men below age 
<55 years, to 3.8 for men aged 70+ years (Supplementary Table 7 & 8).There was 
no difference between fit of the model with a continuous covariate for PRS and the 
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model with separate parameters for percentiles of the PRS (P=0.24). In particular, 
the predicted ORs for the top 1% and the bottom 1% of the population, based on a 
log-linear model, did not differ from that observed. 
 
To estimate the absolute risk of PrCa for different risk groups defined by the 
combined genotypes at the 25 PrCa susceptibility loci, we fitted a logistic regression 
model that It included parameters for PRS (in 7 categories) together with family 
history of PrCa once with (Supplementary Table 7) and once without a PRS x age at 
diagnosis interaction term (Table 3). We used both models (adjusted for age at 
diagnosis and family history) in order to estimate effect sizes for PRS. Then we used 
the UK age-specific incidences of PrCa (0 to 85+ years) (14) to estimate age-specific 
absolute risks of PrCa in the general population after considering competing causes 
of death for fourteen risk groups defined by PRS and family history (seven PRS risk 
groups and two family history, see methods). Based on this analysis, the absolute 
risk of PrCa by age 85 for a man in the top 1% of the risk distribution with family 
history of PrCa was 65.8% (67.1% in a model not allowing for interaction) and for a 
man in the lowest 1% was 3.65% (3.67% in a model not allowing for  interaction). 
The absolute risk for a man in the top 1% of the risk distribution with no family 
history of PrCa was 35.0% (36.1% in a model not allowing for interaction) and 1.46% 
(1.47% in a model not allowing for interaction) for someone in the lowest 1%. By 
comparison, the estimated absolute risk for a man in the 25-75% category was 
10.2% in the absence of a family history of PrCa, and 23.7% for a man with family 
history (Figure 1 & 2, Supplementary Figure 1 & 2).  
 
Discussion 
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These results demonstrate that risk profiling based on SNPs can identify men at 
substantially increased or reduced risk of PrCa. We derived a PRS based on a sum 
of SNP genotypes, weighted by their per-allele log ORs. The estimated ORs for the 
highest and lowest 1% of the population (4.2 and 0.14, respectively) were consistent 
with those predicted under a simple polygenic model in which the log OR increases 
linearly with the PRS.  We also showed that the effect size, measured by OR per 
unit PRS, was higher at younger ages. As expected, the majority of loci, and the 
PRS, showed a stronger effect for familial cases. In a logistic regression model, both 
PRS and family history were independently associated with PrCa risk. The OR due 
to family history was attenuated after adjustment for the PRS (from 2.63 to 2.50), as 
expected given that family history is, at least in part, a reflection of genetic 
susceptibility. However, the degree of attenuation (5% on a log-scale) was markedly 
less than 18%, the estimated contribution of these 25 loci  to the familial risk of PrCa 
estimated based on their ORs and allele frequencies in this study (see methods). 
The reason for this difference is unclear but might reflect interactions between the 
known susceptibility loci summarised in the PRS and other factors influencing family 
history.  
 
In order to investigate the added value of PRS, once we estimated the absolute risk 
for individuals with family history without fitting their PRS information and then 
repeated the same procedure after adding their PRS information. The absolute risk 
of PrCa for a man at age 85 with family history was estimated to be 26.5% when 
PRS information was ignored. When we incorporated PRS information, a man at age 
85 ,depend on his PRS risk group, could have an absolute risk ranging from 3.67% 
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(if a man is in the bottom 1% of the risk distribution) to 67.1% (if a man is in the top 
1% of the risk distribution, Supplementary Figure 1 and 3). These observations 
indicate that family history and the PRS independently influence risk and can be 
combined to provide stronger discrimination. 
 
Chatterjee et al. derived theoretical estimates for the predictive performance of 
polygenic models for ten complex traits or common diseases, including PrCa, using 
published estimates for individual SNPs (18). They estimated that ~7% of the 
population will be at two-fold risk or greater for PrCa. We estimated, empirically, that 
the (average) risk to men in the 90-99% category of the PRS was 2.41 fold, relative 
to the population median, or approximately 2 fold relative to the population mean. 
However, this is an average risk over the 90-99% category, so that the percentile of 
the PRS at which the risk exceeds 2 fold will be >90%. Based on the estimated 
log(OR) per standardised PRS, approximately 6% of men will have a risk of greater 
than twofold, very close to the estimate of Chatterjee et al (18). 
 
These results show that genetic risk profiling using SNPs could be useful in defining 
men at high risk for the disease for targeted prevention and screening programs. 
The benefits of screening, relative to the costs, will be most favourable among men 
at higher risk. If, for example, the benefit-cost ratio is favourable for screening men 
at a greater than two-fold risk, the PRS provides an effective method for identifying 
such men. 
 
While these analyses demonstrate the value of SNPs for risk prediction, a risk model 
could be improved in various ways. The analyses presented here are based on the 
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25 loci first identified to be associated with PrCa. Recently, however, additional loci 
have been identified (13, 19) and more than 100 common susceptibility loci are now 
known. In total, these loci increase the estimated proportion of the familial risk to 
33% (19). Incorporating all known loci into a PRS should improve the predictive 
value of risk profiles.  
 
Additionally, the analyses presented here consider family history as a binary 
(yes/no) covariate. It is known that the risk of PrCa is dependent on both the number 
of affected relatives and their ages. MacInnis et al. (12, 20) have shown using 
segregation analysis that the familial aggregation of PrCa can be modelled as the 
combined effect of a recessive allele and a polygenic component, and that the 
polygenic component can be further partitioned into a component due to measured 
SNPs and an unmeasured component. This approach should provide more powerful 
prediction, particularly in families with multiple cases of the disease. Finally, it is 
known that serum or urine PSA level is associated with PrCa risk, with the 
association persisting for several decades. Although some of the risks SNPs are 
also related to PSA level in the expected direction, the PSA level is only weakly 
correlated with PRS, indicating that incorporating PSA level and potentially other 
markers such as MSMB (21) into a risk algorithm should further improve the 
discrimination (22). 
 
The absence of clear differences in the relative risk associated with SNPs by 
disease aggressiveness, even in this very large study, is striking. We did not find any 
convincing evidence for differences in the predictive values of the PRS by disease 
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aggressiveness. The effect size was higher for less aggressive disease, but the 
difference was still small (1.75 vs. 1.65). This result is in contrast to the clear 
differences in SNP associations by disease pathology seen in other diseases, for 
example in breast and ovarian cancer, and indicates that aggressive and non-
aggressive disease, at least as measured by Gleason score, share these genetic 
risk factors as a common aetiology.  
 
Analysis of pairwise combinations of SNPs did not identify any clear examples of 
departure from a multiplicative model, after adjusting for multiple testing. We did, 
however, find an excess of interactions at the P<0.01 level over the number that 
would be expected by chance. This suggests that interactions on this scale likely to 
exist, but their effect sizes are small and that very large sample sizes, exemplified by 
this collaborative study, will be required to identify and characterise them. If such 
interactions could be identified reliably, they may improve the predictive value of the 
risk profiling, and also provide insights into the biological interactions between the 
underlying risk variants. 
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Table 1: Total numbers of cases and controls used in the analyses        
        Study Controlsa Casesa Totala 
GWAS Stage 3  4,076 4,505 8,581 
PRACTICAL 16,050 15,783 31,833 
Total 20,126 20,288 40,414 
Totalb  18,343 16,643 34,986 
a
 Analyses were restricted to men of European ancestry (see text).  
b
Total after excluding 5 studies that oversampled cases with family history. 
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Table 2: Summary results of 25 SNPs using PRACTICAL and GWAS Stage 3 
datasets in European. 
 
Marker
a 
Chr/Nearby Gene 
 
 
Alleles
b 
Position
c 
 
MAF
d
 
 
Per allele
e
 OR 
(95%CI) 
 
Het OR
 e,f 
(95%CI) 
 
Hom OR
e,g 
(95%CI) 
 
P-value
h
 
 
 
P-value
i
 
 
rs721048 
2 / EHBP1 
C/T 
63131731 
0.18 1.11 
(1.07-1.16) 
1.09 
(1.04-1.15) 
1.32 
(1.17-1.48) 
9.8x10
-8
 0.13 
rs1465618 
2 / THADA 
G/A 
43553949 
0.2150 1.07 
(1.03-1.11) 
1.08 
(1.03-1.13) 
1.14 
(1.03-1.26) 
1.9x10
-4 
 
0.39 
rs12621278 
2 / ITGA6 
A/G 
173311553 
0.06 .75 
(.70-.80) 
.76 
(.71-.82) 
.38 
(.24-.58) 
4.9x10
-17
 0.57 
rs2660753 
3 / Unknown 
G/A 
87110674 
0.10 1.12 
(1.06-1.18) 
1.12 
(1.06-1.19) 
1.32 
(1.09-1.61) 
1.2x10
-5
 0.73 
rs17021918 
4 / PDLIM5 
G/A 
95562877 
0.35 .88 
(.85-.91) 
.86 
(.83-.90) 
.80 
(.74-.85) 
6.7x10
-15 
 
0.39 
rs12500426 
4 / PDLIM5 
G/T 
95514609 
0.46 1.10 
(1.06-1.13) 
1.11 
(1.06-1.18) 
1.20 
(1.12-1.28) 
4.8x10
-8
 0.54 
rs7679673 
4 / TET2 
C/A 
106061534 
0.40 .88 
(.85-.90) 
.87 
(.83-.91) 
.77 
(.72-.82) 
1.0x10
-16
 0.08 
rs9364554 
6 / SLC22A3 
C/T 
160833664 
0.29 1.10 
(1.06-1.14) 
1.12 
(1.07-1.18) 
1.18 
(1.09-1.27) 
4.8x10
-8 
 
0.85 
rs10486567 
7 / JAZF1 
G/A 
27976563 
0.23 .85 
(.82-.89) 
.86 
(.81-.91) 
.72 
(.63-.81) 
4.5x10
-12 
 
0.21 
rs6465657 
7 / LMTK2 
A/G 
97816327 
0.46 1.10 
(1.06-1.13) 
1.09 
(1.04-1.15) 
1.21 
(1.13-1.28) 
3.4x10
-9
 0.32 
rs1447295 
8 / Unknown 
G/T 
128485038 
0.11 1.41 
(1.35-1.48) 
1.41 
(1.34-1.49) 
2.01 
(1.69-2.41) 
1.4x10
-46
 0.50 
rs6983267 
8 / Unknown 
C/A 
128413305 
0.49 .82 
(.79-.85) 
.80 
(.76-.85) 
.67 
(.63-.72) 
2.3x10
-35 
 
0.61 
rs16901979 
8 / Unknown 
G/T 
128124916 
0.03 1.56 
(1.44-1.68) 
1.55 
(1.43-1.69) 
2.39 
(1.47-3.86) 
3.8x10
-28
 0.29 
rs2928679 
8 / SLC25A37 
C/T 
23438975 
0.48 1.04 
(1.01-1.07) 
1.03 
(.97-1.09) 
1.08 
(1.01-1.16) 
.02 0.10 
rs1512268 
8 / NKX3.1 
G/A 
23526463 
0.43 1.13 
(1.10-1.17) 
1.13 
(1.08-1.19) 
1.29 
(1.21-1.37) 
2.6x10
-16
 0.19 
rs4962416 
10 / CTBP2 
A/G 
126696872 
0.28 1.04 
(1.01-1.08) 
1.03 
(.98-1.08) 
1.11 
 (1.02-1.21) 
.02
 
0.68 
rs10993994 
10 / MSMB 
G/A 
51549496 
0.39 1.24 
(1.20-1.28) 
1.21 
(1.15-1.27) 
1.56 
(1.46-1.66) 
7.9x10
-41
 0.36 
rs7931342 
11 / Unknown 
C/A 
68994497 
0.50 .84 
(.81-.86) 
.86 
(.82-.91) 
.70 
(.65-.74) 
4.8x10
-27 
 
0.86 
rs7127900 
11 / Unknown 
G/A 
2233574 
0.19 1.23 
(1.18-1.28) 
1.24 
(1.18-1.30) 
1.47 
(1.32-1.65) 
6.3x10
-26
 0.63 
rs4430796 
17 / HNF1B 
A/G 
36098040 
0.48 .81 
(.79-.84) 
.81 
(.77-.85) 
.66 
(.62-.71) 
2.7x10
-38 
 
0.79 
rs11649743 
17 / HNF1B 
G/A 
36074979 
0.19 .88 
(.85-.92) 
.88 
(.83-.92) 
.79 
(.70-.90) 
5.6x10
-10 
 
0.25 
rs1859962 
17 / Unknown 
T/G 
69108753 
0.48 1.17 
(1.14-1.21) 
1.22 
(1.15-1.28) 
1.38 
(1.30-1.47) 
3.7x10
-24
 0.19 
rs2735839 
19 / KLK2/KLK3 
G/A 
51364623 
0.15 .81 
(.77-.85) 
.82 
(.78-.86) 
.62 
(.53-.73) 
1.1x10
-19
 0.06 
rs5759167 
22 / BIL/TTLL1 
G/T 
43500212 
0.50 .84 
(.82-.87) 
.83 
(.79-.87) 
.71 
(.67-.76) 
3.4x10
-28 
 
0.87 
rs5945619 
X / NUDT11 
T/C 
51241672 
0.36 1.13 
(1.10-1.16) 
- 1.28 
(1.22-1.35) 
1.9x10
-20
 0.10 
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a
dbSNP rs number, 
b
Major/minor allele, based on the frequencies in controls in PRACTICAL III data, 
c
Build 37 
position,
 d
 MAF in controls in combined European dataset. 
e
OR = odds ratio (minor allele) from a logistic 
regression using all European samples stratified by studies with no adjustment, 
f
OR in heterozygotes, relative to 
major allele homozygotes, 
g
OR in minor allele homozygotes, relative to major allele homozygotes, 
h
Cochran-
Armitage test for trend.
 i 
Heterogeneity P-value among studies 
 
 
Table 3: Odds ratios for PrCa by percentile of the PRS and family history.   
Percentiles OR
a,b 
OR
a,c
 
 
 
 
PRS Group  
< 1% 1       (baseline) 0.14 (0.08-0.24) 
1-10% 2.98 (1.66-5.35) 0.41 (0.36-0.47) 
10-25% 4.59 (2.58-8.17) 0.63 (0.57-0.70) 
25-75% 7.23 (4.08-12.80) 1      (baseline) 
75-90% 12.13 (6.83-21.54) 1.68 (1.54-1.83) 
90-99% 16.70 (9.38-29.72) 2.31 (2.09-2.56) 
>= 99%  30.63 (16.36-57.34) 4.24 (3.24-5.53) 
Family History 2.52 (2.29-2.78)
 
2.52 (2.29-2.78)
 
 
a
ORs obtained by fitting PRS group, family history and age at diagnosis jointly. 
b
ORs compared to men in the 1st percentile as baseline. 
c
ORs compared to men in the 25
th
-75
th
 percentile as baseline. 
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Figure Legend  
 
Figure 1: Absolute risk of PrCa by age in men with family history. 
 
Figure 2: Absolute risk of PrCa by age in men with no family history. 
 
 
 
 
Figure 1 
Figure 2 
 Supplementary table 1: Total number of cases and controls in PRACTICAL III and 
GWAS stage 3 by population and study 
 
Study Ethnicity No. Study Acronym Study Design Controls
b 
Cases
b 
Total
b 
Age
c
 
 
 
 
 
 
 
 
PRACTICAL 
PIII 
 
 
 
 
 
 
 
 
 
European 
1 Aarhus       Case-Control 592 650 1,242 64 (36-88) 
2 BiPAS  Case-Control 88 176 264 69 (51-85) 
3, 4 CPCS 1 & 2 Case-Control
 
1,474 413 1,887 69 (50-94) 
5 ESTHER  Case-Control 329 330 659 66 (51-75) 
6 FHCRC  Case-Control 1,265 1,309 2,574 60 (35-74) 
7 HaPCS  Case-Control 485 499 984 66 (41-81) 
8 MAYO 
a
 Case-Control 527 884 1,411 65 (41-86) 
9 MCCS       Case-Control
d 
2,332 491 2,823 69 (50-85) 
10 MEC  Cohort Study
e 
396 448 844 59 (46-71) 
11 MOFFITT  Case-Control 372 702 1,074 69 (50-87) 
12 PCFS
a
             Case-Control
f
 82 76 158 65 (42-87) 
13 PCMUS  Case-Control 193 173 366 70 (47-90) 
14 Poland  Case-Control 572 574 1,146 68 (43-90) 
15 ProtecT  Case-Control
g 
2,194 2,204 4,398 63 (45-72) 
16 QLD  3 studies 
h 
1,394 1,346 2,740 63 (40-89) 
17 SFPCS (NC-CCPC) Case-Control 219 302 521 65 (44-80) 
18 TAMPERE  Case-Control 1,851 2,496 4,347 67 (37-95) 
19 TASPRAC
a
 Case-Control 337 492 829 62 (44-82) 
20 UKGPCS Case-Control 212 392 604 60 (36-85) 
21 ULM 
a
 Case-Control 379 702 1,081 64 (42-84) 
22 USC  Case-Control 295 488 783 68 (46-94) 
23 UTAH 
a
 Case-Control 240 466 706 67 (42-87) 
24 Valais  Case-Control 222 170 392 65 (49-84) 
Total 16,050 15,783 31,833 64 (35-95) 
 
 
GWAS 
stage 3 
 
European 
  MCCS       Case-Control
d 548 327 875 69 (49-85) 
 PCFS
b
             Case-Control
f 218 1,025 1,243 57 (41-87) 
25 SEARCH      Case-Control 1,365 1,450 2,815 63 (44-73) 
 UKGPCS  Case-Control 1,945 1,703 3,648 61 (36-85) 
Total 4,076 4,505 8,581 61 (36-87) 
 
Total European (PRACTICAL & GWAS stage 3) 20,126 20,288 40,414 64 (35-95) 
Total European (PRACTICAL & GWAS stage 3)  excluding familial studies 18,343 16,643 34,986 64 (35-95) 
 
a 
Studies that oversampled cases with family history. 
b 
The number of samples given here are those 
that were available for this analysis. These may differ from the numbers for the complete studies 
given in the Supplementary Notes. 
c 
Mean age at diagnosis for cases (min-max). 
d
 Nested case-
control. 
e 
Population-based prospective cohort study. 
f 
Population-based with cases from informative 
families. 
g 
PSA screening selected cases-controls. 
h 
One Cohort study, one hospital based and one 
prospective cohort study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 2: Data information for family history and age at 
diagnosis/observation 
   
(a): All samples excluding studies with familial design 
Samples Cases Controls Total 
Without family history 9,740 8,305 18,045 
With family history 2,165 999 3,164 
Total having information 11,905 9,304 21,209 
Missing family history information 4,738 9,039 13,777 
Total  16,643 18,343 34,986 
Family history information 71.53% 50.72% 60.62% 
Percentage of samples with family history among those 
having family history information 
18.19% 10.74% 14.92% 
Age at diagnosis/recruitment  16,503 14,647 31,150 
Mean age (range) 64 (35-95) 58.3 (18-99) 61.5 (18-99) 
Missing age information 140 3,696 3,836 
Total 16,643 18,343 34,986 
Percentage of samples with age information 99.16% 79.85% 89.04% 
(b): All samples 
Samples Cases Controls Total 
Without family history 11,940 9,451 21391 
With family history 3,486 1,397 4,883 
Total having information 15,426 10,848 26,274 
Missing family history information 4,862 9,278 14,140 
Total  20,288 20,126 40,414 
Family history information 76.04% 53.90% 65.01% 
Percentage of samples with family history among those 
having family history information 
22.60% 12.88% 18.58% 
Age at diagnosis/recruitment  20,137 16,262 36,399 
Mean age (range) 64 (35-95) 58.7 (18-99) 61.6 (18-99) 
Missing age information 151 3,864 4,015 
Total 20,288 20,126 40,414 
Percentage of samples with age information 99.26% 80.80% 90.07% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 3: Grade-specific and family history-specific odds ratios. 
                               
a
 P-value for difference in per-allele OR between GS 8+ and GS <8
 
b
 P-value for trend in OR by Gleason score as an ordinal variable 
c
 P-value for difference in per-allele OR between Family History Yes and No
 
d
 Polygenic Risk Score adjusted for age at diagnosis and family history. For Family history, PRS 
adjusted for age at diagnosis (OR is based on per unit increase of PRS).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable/ 
Marker 
 
GS < 8 
 
GS 8 + 
 
P
a
 
 
P
b
  
Family History (FH)  
P
c
 No Yes 
PRS
d
 1.75 (1.68-1.82) 1.65 (1.54-1.77) .37 NA 1.70 (1.64-1.76) 1.79 (1.63-1.96) 1.8x10
-4
 
rs721048  1.13 (1.08-1.18) 1.12 (1.02-1.23) .81 .96 1.09 (1.06-1.16) 1.11 (1.04-1.19) .06 
rs1465618  1.08 (.1.04-1.13) 1.00 (.92-1.09) .09 .22 1.07 (1.03-1.12) 1.13 (1.05-1.21) .02 
rs12621278  .76 (.70-.82) .75 (.64-.88) .79 1.00 .72 (.66-.78) .77 (.67-.88) .21 
rs2660753  1.12 (1.05-1.19) 1.05 (.94-1.18) .29 .82 1.15 (1.08-1.22) 1.07 (.98-1.18) .87 
rs17021918  .88 (.85-.91) .94 (.88-1.01) .03 .007 .87 (.84-.90) .92 (.86-.98) .21 
rs12500426  1.11 (1.07-1.15) 1.02 (.95-1.10) .05 .29 1.10 (1.06-1.14) 1.10 (1.03-1.18) .43 
rs7679673  .86 (.83-.89) .90 (.84-.97) .16 .15 .90 (.87-.93) .84 (.79-.89) 2.9x10
-5
 
rs9364554  1.11 (1.07-1.16) 1.03 (.95-1.12) .16 .60 1.08 (1.03-1.12) 1.18 (1.11-1.26) .15 
rs10486567 .83 (.79-.88) .81 (.73-.90) .79 .90 .87 (.83-.92) .80 (.73-.88) .01 
rs6465657  1.09 (1.05-1.13) 1.06 (.99-1.14) .64 .21 1.08 (1.04-1.12) 1.14 (1.07-1.21) .07 
rs1447295  1.41 (1.34-1.49) 1.48 (1.33-1.64) .64 .001 1.41 (1.33-1.49) 1.54 (1.42-1.68) 1.4x10
-6
 
rs6983267  .82 (.79-.85) .84 (.79-.91) .68 .85 .83(.80-.86) .79 (.75-.84) .003 
rs16901979  1.48 (1.35-1.62) 1.77 (1.50-2.08) .06 .13 1.58 (1.44-1.73) 1.63 (1.42-1.87) .05 
rs2928679  1.05 (1.01-1.09) 1.00 (.93-1.08) .51 .33 1.05 (1.01-1.09) 1.08 (1.02-1.15) .06 
rs1512268  1.16 (1.12-1.20) 1.04 (.97-1.12) .002
 
.02 1.13 (1.09-1.17) 1.19 (1.12-1.26) .16 
rs4962416  1.06 (1.02-1.11) 1.02 (.94-1.11) .35 .80 1.04 (.99-1.08) 1.07 (1.00-1.14) .13 
rs10993994  1.23 (1.19-1.28) 1.21 (1.13-1.30) .82 .80 1.24 (1.20-1.29) 1.32 (1.25-1.41) .002 
rs7931342  .85 (.82-.88) .79 (.74-.86) .19 .50 .85 (.82-.89) .80 (.75-.85) 9.6x10
-5
 
rs7127900  1.28 (1.22-1.34) 1.14 (1.04-1.24) .01 .003 1.21 (1.16-1.27) 1.27 (1.18-1.37) .01 
rs4430796  .80 (.77-.83) .79 (.74-.85) .98 .40 .82 (.79-.85) .77 (.73-.82) .004 
rs11649743  .87 (.83-.91) .87 (.79-.95) .94 .30 .89 (.85-.94) .83 (.77-.90) .003 
rs1859962  1.19 (1.15-1.24) 1.13 (1.05-1.21) .20 .78 1.17 (1.13-1.21) 1.21 (1.14-1.28) .007 
rs2735839  .79 (.75-.83) .93 (.83-1.03) .002 .003 .81 (.76-.85) .80 (.73-.88) .31 
rs5759167  .85 (.82-.88) .85 (.80-.91) .85 .58 .85 (.82-.88) .82 (.77-.86) .04 
rs5945619  1.13 (1.10-1.17) 1.16 (1.09-1.23) .54 .44 1.14 (1.10-1.18) 1.10 (1.04-1.16) .81 
 Supplementary Table 4: PSA levels by genotype in controls.  
            
Marker Geometric mean PSA (95%CI) P-value
a 
rs721048 
 
CC CT TT  
2.07 (1.63-2.50) 1.78 (1.39-2.16) 2.04 (.70-3.38) .11 
rs1465618 
 
GG GA AA  
1.42 (1.37-1.47) 1.40 (1.32-1.47) 1.30 (1.16-1.45) .29 
rs12621278 
 
AA AG GG  
1.94 (1.61-2.26) 2.03 (1.08-2.97) 1.68 (1.14-2.23) .81 
rs2660753 
 
GG GA AA  
1.90 (1.58-2.22) 2.06 (1.37-2.75) 7.01 (-4.66-18.67) .21
 
rs17021918 
 
GG GA AA  
1.94 (1.48-2.39) 1.87 (1.42-2.31) 2.26 (1.21-3.30) .34 
rs12500426 
 
GG GT TT  
2.07 (1.43-2.71) 2.24 (1.65-2.83) 1.98 (1.07-2.88) .19 
rs7679673 
 
CC CA AA  
1.75 (1.34-2.16) 2.25 (1.69-2.81) 1.48 (1.34-1.63) .38 
rs9364554 
 
CC CT TT  
2.40 (1.79-3.00) 1.63 (1.36-1.90) 1.38 (1.27-1.49) .25 
rs10486567 
 
GG GA AA  
2.80 (1.90-3.70) 2.26 (1.36-3.16) 1.44 (1.17-1.71) .12 
rs6465657 
 
AA AG GG  
1.78 (1.35-2.22) 2.05 (1.57-2.53) 2.07 (1.38-2.76) .83 
rs1447295 
 
GG GT TT  
2.08 (1.70-2.46) 1.54 (1.25-1.84) 1.11 (.93-1.29) .03 
rs6983267 
 
CC CA AA  
2.04 (1.32-2.76) 2.12 (1.65-2.59) 1.61 (1.22-1.99) .01 
rs16901979 
 
GG GT TT  
1.94 (1.62-2.26) 1.56 (1.38-1.75) 1.30 (.69-1.91) .18 
rs2928679 
 
CC CT TT  
1.61 (1.31-1.92) 2.17 (1.63-2.70) 1.91 (1.26-2.57) .27 
rs1512268 
 
GG GA AA  
1.68 (1.30-2.06) 2.13 (1.59-2.66) 1.99 (1.33-2.64) .004 
rs4962416 
 
AA AG GG  
2.06 (1.59-2.53) 1.97 (1.50-2.45) 1.35 (1.21-1.49) .73 
rs10993994 
 
GG GA AA  
2.15 (1.54-2.77) 1.68 (1.38-1.98) 2.45 (1.50-3.40) 3.5x10
-5
 
rs7931342 
 
CC CA AA  
2.36 (1.62-3.09) 2.06 (1.57-2.56) 1.41 (1.33-1.49) .11 
rs7127900 
 
GG GA AA  
1.90 (1.54-2.25) 1.99 (1.35-2.64) 2.90 (.33-5.47) .03 
rs4430796 
 
AA AG GG  
1.54 (1.34-1.74) 2.08 (1.61-2.54) 2.22 (1.41-3.03) .38 
rs11649743 
 
GG GA AA  
2.13 (1.69-2.57) 1.57 (1.27-1.86) 2.59 (.44-4.75) .84 
rs1859962 
 
TT TG GG  
2.05 (1.49-2.60) 1.99 (1.50-2.48) 1.84 (1.34-2.33) .17 
rs2735839 
 
GG GA AA  
2.07 (1.70-2.43) 1.79 (1.15-2.42) 1.08 (.83-1.32) 2.8x10
-13 
rs5759167 
 
GG GT TT  
1.86 (1.28-2.43) 2.16 (1.63-2.69) 1.59 (1.26-1.93) .37 
rs5945619 
 
TT TC CC  
2.63 (1.80-3.46)  2.24 (1.53-2.94) .09 
  
a
Test for trend in log (PSA) by allele dose 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 5: Age-specific odds ratios. 
 
Variable/ 
Marker 
Age at diagnosis (years)  
Ptrend
a
 <55 55-59 60-64 65-69 70+ 
PRS
b
 1.76 
(1.62-1.92) 
1.85 
(1.72-1.98) 
1.70 
(1.59-1.82) 
1.70 
(1.57-1.83) 
1.48 
(1.37-1.60) 
2.6x10
-4
 
rs721048 1.09 
(.99-1.19) 
1.13 
(1.06-1.21) 
1.12 
(1.05-1.19) 
1.13 
(1.06-1.20) 
1.07 
(.99-1.15) 
.86 
rs1465618 
 
1.14 
(1.04-1.24) 
1.07 
(1.01-1.13) 
1.09 
(1.03-1.15) 
1.09 
(1.03-1.16) 
1.01 
(.94-1.07) 
.03 
rs12621278 
 
.59 
(.49-.71) 
.76 
(.67-.86) 
.67 
(.60-.76) 
.79 
(.71-.88) 
.83 
(.73-.94) 
1.9x10
-5
 
rs2660753 
 
1.16 
(1.04-1.29) 
1.10 
(1.01-1.20) 
1.18 
(1.09-1.28) 
1.13 
(1.05-1.22) 
1.04 
(.95-1.14) 
.12 
rs17021918 
 
.83 
(.77-.90) 
.86 
(.81-.91) 
.91 
(.87-.96) 
.89 
(.85-.94) 
.89 
(.84-.94) 
.06 
rs12500426 
 
1.17 
(1.08-1.27) 
1.16 
(1.09-1.24) 
1.09 
(1.03-1.15) 
1.05 
(1.00-1.11) 
1.07 
(1.02-1.13) 
.08 
rs7679673 
 
.87 
(.81-.94) 
.87 
(.82-.92) 
.90 
(.85-.94) 
.86 
(.81-.90) 
.89 
(.85-.94) 
.08 
rs9364554 
 
1.15 
(1.06-1.24) 
1.13 
(1.07-1.20) 
1.08 
(1.02-1.14) 
1.08 
(1.03-1.14) 
1.07 
(1.01-1.14) 
.07 
rs10486567 
 
.78 
(.69-.87) 
.82 
(.76-.89) 
.90 
(.84-.97) 
.87 
(.81-.93) 
.85 
(.78-.92) 
.19 
rs6465657 
 
1.14 
(1.07-1.23) 
1.11 
(1.05-1.17) 
1.11 
(1.05-1.16) 
1.06 
(1.01-1.11) 
1.09 
(1.03-1.15) 
.69 
rs1447295 
 
1.42 
(1.28-1.57) 
1.43 
(1.33-1.55) 
1.39 
(1.29-1.49) 
1.40 
(1.30-1.51) 
1.45 
(1.33-1.58) 
.75 
rs6983267 
 
.80 
(.74-.85) 
.80 
(.75-.84) 
.80 
(.76-.84) 
.82 
(.78-.87) 
.90 
(.85-.95) 
.06 
rs16901979 
 
1.54 
(1.31-1.81) 
1.53 
(1.35-1.73) 
1.53 
(1.36-1.73) 
1.56 
(1.39-1.75) 
1.60 
(1.39-1.84) 
.06 
rs2928679 
 
1.08 
(1.01-1.17) 
1.03 
(.97-1.09) 
1.02 
(.96-1.07) 
1.04 
(.99-1.10) 
1.04 
(.98-1.11) 
.09 
rs1512268 
 
1.11 
(1.04-1.20) 
1.19 
(1.13-1.26) 
1.15 
(1.09-1.21) 
1.13 
(1.08-1.19) 
1.10 
(1.05-1.16) 
.70 
rs4962416 
 
1.12 
(1.03-1.21) 
1.01 
(.95-1.07) 
1.08 
(1.02-1.14) 
1.01 
(.96-1.07) 
1.01 
(.95-1.09) 
.37 
rs10993994 
 
1.35 
(1.26-1.45) 
1.28 
(1.22-1.36) 
1.21 
(1.15-1.28) 
1.23 
(1.17-1.29) 
1.16 
(1.10-1.23) 
.009 
rs7931342 
 
.83 
(.77-.89) 
.84 
(.79-.88) 
.82 
(.77-.86) 
.87 
(.82-.91) 
.86 
(.81-.92) 
.22 
rs7127900 
 
1.39 
(1.27-1.51) 
1.24 
(1.16-1.32) 
1.22 
(1.15-1.30) 
1.24 
(1.17-1.32) 
1.15 
(1.08-1.23) 
.01 
rs4430796 
 
.80 
(.75-.86) 
.77 
(.73-.82) 
.81 
(.77-.85) 
.85 
(.81-.89) 
.83 
(.79-.89) 
.12 
rs11649743 
 
.91 
(.83-.99) 
.87 
(.81-.93) 
.85 
(.79-.90) 
.91 
(.85-.97) 
.90 
(.83-.97) 
.33 
rs1859962 
 
1.25 
(1.17-1.34) 
1.20 
(1.14-1.27) 
1.24 
(1.18-1.30) 
1.13 
(1.07-1.18) 
1.11 
(1.05-1.18) 
.04 
rs2735839 
 
.77 
(.70-.86) 
.72 
(.67-.79) 
.77 
(.72-.83) 
.85 
(.79-.91) 
.91 
(.84-.99) 
.001 
rs5759167 
 
.80 
(.75-.86) 
.84 
(.79-.88) 
.84 
(.80-.88) 
.84 
(.80-.88) 
.87 
(.82-.91) 
.11 
rs5945619 
 
1.14 
(1.07-1.21) 
1.19 
(1.14-1.25) 
1.16 
(1.12-1.21) 
1.11 
(1.07-1.15) 
1.07 
(1.02-1.12) 
.0003 
 
a 
1df trend test for trend in OR by age, using case only analysis.  
b
 OR is based on per unit increase of PRS. 
 
 
 
 Supplementary Table 6: The results of 29 pair wise interaction of 25 SNPs 
 significant at P <0.05 (29 out of 300 interactions; Bonferroni correction 
0.05/300=1.67x10-4).  
 
Pair P-value
a 
Pair P-value
a 
rs721048 x rs17021918 0.05 rs9364554 x rs1859962 0.003 
rs1465618 x rs17021918 0.004 rs10486567 x rs16901979 0.01 
rs1465618 x rs12500426 0.001 rs10486567 x rs4962416 0.02 
rs1465618 x rs7679673 0.03 rs10486567 x rs4430796 0.004 
rs1465618 x rs7127900 0.02 rs1447295 x rs7127900 0.04 
rs2660753 x rs12500426 0.02 rs16901979 x rs10993994 0.001 
rs2660753 x rs16901979 0.04 rs4962416 x rs7931342 0.03 
rs2660753 x rs2928679 0.05 rs4962416 x rs4430796 0.01 
rs2660753 x rs5759167 0.04 rs4962416 x rs2735839 0.001 
rs17021918 x rs7679673 0.01 rs10993994 x rs4430796 0.02 
rs12500426 x rs7679673 0.02 rs7931342 x rs4430796 0.02 
rs12500426 x rs11649743 0.04 rs7931342 x rs2735839 0.05 
rs12500426 x rs5759167 0.04 rs7127900 x rs4430796 0.02 
rs7679673 x rs5759167 0.01 rs4430796 x rs2735839  0.004 
rs9364554 x rs16901979 0.001   
a
 Likelihood ratio test  
 
 
 
 
 
 
 
Supplementary Table 7: Estimated odds ratios of PRS percentiles adjusted for age 
at diagnosis of PrCa (five categories) in a model allowing for an interaction between 
PRS and Age.   
  
Covariate  Odds ratio (95% CI)  P-value Odds ratio
a
 (95% CI) P-value 
 
 
 
PRS Group 
 
 
 
<1%  1  0.10 (0.05-0.18) 2.4x10
-13
 
1-10%   3.43 (1.89-6.23) 5.3x10
-5
 0.33 (0.27-0.41) 3.7x10
-26 
10-25%  5.90 (3.22-10.82) 9.5x10
-9
 0.57 (0.50-0.65)
 
2.5x10
-18 
25-75%  10.33 (5.53-19.29) 2.5x10
-13
 1
  
75-90%  19.12 (9.92-36.86) 1.3x10
-18
 1.85 (1.66-2.07)
 
6.6x10
-28 
90-99%  28.92 (14.50-57.69) 1.3x10
-21
 2.80 (2.38-3.30)
 
1.5x10
-34 
>=99%   58.11 (26.99-125.11) 3.1x10
-25
 5.63 (4.05-7.82)
 
6.4x10
-25 
Family History (Yes/No) 2.52 (2.29-2.78) 4.7x10
-77
 2.52 (2.29-2.78) 4.7x10
-77
 
PRS x Age at Diagnosis 
 interaction
b
 
0.97 (0.95-0.99) 0.003 0.97 (0.95-0.99)
 
0.003
 
a
 Odds Ratios were compared to median risk group.
 
b 
PRS and age at diagnosis both as categorical variables. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Table 8: Estimated odds ratios used for estimating absolute risk  
 
(a) Model without interaction 
Family History (FH)  Risk Group 
<1% 1-10% 10-25% 25-75% 75-90% 90-99% >=99% 
No 0.14 0.41 0.63 1.00 1.68 2.31 4.24 
Yes 0.35 1.04 1.60 2.52 4.24 5.83 10.70 
(b) Model with interactiona (samples with no FH) 
Age group <1% 1-10% 10-25% 25-75% 75-90% 90-99% >=99% 
<55 0.10 0.33 0.57 1.00 1.85 2.80 5.63 
55-59 0.09 0.31 0.55 1.00 1.79 2.62 5.09 
60-64 0.08 0.29 0.53 1.00 1.73 2.45 4.60 
64-69 0.07 0.27 0.52 1.00 1.67 2.29 4.16 
70+ 0.06 0.25 0.50 1.00 1.62 2.14 3.76 
(c) Model with interactiona (samples with FH) 
Age group <1% 1-10% 10-25% 25-75% 75-90% 90-99% >=99% 
<55 0.24 0.84 1.44 2.52 4.67 7.07 14.21 
55-59 0.22 0.78 1.39 2.52 4.52 6.61 12.84 
60-64 0.20 0.73 1.35 2.52 4.37 6.18 11.60 
64-69 0.18 0.68 1.30 2.52 4.22 5.78 10.49 
70+ 0.16 0.64 1.26 2.52 4.08 5.40 9.48 
a 
Interaction between PRS and age at diagnosis both as categorical variables. 
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SUPPLEMENTARY NOTES: DESCRIPTION OF OPA AND THE PRACTICAL 
CONSORTIUM GROUPS 
All studies were approved by the appropriate ethics committees. A list of the groups 
is in Supplementary Table 1.  
 
CPCS1+2:  
The CPCS (Copenhagen Prostate Cancer Study) 1 + 2, Copenhagen, Denmark 
The Copenhagen Prostate Cancer Study 1 included 872 unselected patients 
recruited with prostate cancer between 2008-2011 from Herlev Hospital, 
Copenhagen University Hospital, Herlev, Denmark. The Copenhagen Prostate 
Cancer Study 2 included 306 unselected patients with prostate cancer recruited in 
2010-2011 from Rigshospitalet, Copenhagen University Hospital, Copenhagen, 
Denmark. PSA is not routinely screened for in Denmark, and cases are therefore 
mainly clinically detected. Controls were 2,777 (CPCS1) and 798 (CPCS2) prostate 
cancer free men from the general population, whom participated in the Copenhagen 
City Heart Study. Diagnosis of prostate cancer was confirmed by fully trained 
pathologists. All participants were white and of Danish descent. Participants filled out 
questionnaires, gave blood samples for DNA extraction and gave written informed 
consent.  
 
ESTHER 
In the ESTHER study, patients with a first diagnosis of prostate cancer at age 50-75 
years were recruited in hospitals and medical practices in Saarland, a state located 
in southwest Germany, from 2001 to 2003. Controls were selected from participants 
of a general health-check up within the same age range (and frequency matched to 
the cases by 5-year age groups) who were recruited in general practices in Saarland 
in 2000-2002. Cases and controls who were almost exclusively of European 
descent, filled out a detailed standardized questionnaire on life time history of 
potential risk factors and had a blood sample taken, and medical data were 
extracted from medical records. 
 
FHCRC:  Fred Hutchinson Cancer Research Centre, Seattle US 
The study population consists of participants from two population-based case-control 
studies in Caucasian and African American residents of King County, Washington 
 2 
(Study I and Study II), which have been previously described7 Incident cases with 
histologically confirmed PrCa were ascertained from the Seattle-Puget Sound 
Surveillance, Epidemiology and End Results cancer registry.  In Study I, cases were 
diagnosed between January 1, 1993, and December 31, 1996 and were 40-64 years 
of age at diagnosis.  In Study II, cases were diagnosed between January 1, 2002, 
and December 31, 2005 and were 35-74 years of age at diagnosis.  Overall, 2,244 
eligible PrCa patients were identified and 1,754 (78%) were interviewed.  Blood 
samples yielding sufficient DNA for genotyping were drawn from 1,457 (83%) cases 
who completed the study interview.  A comparison group of controls without a history 
of PrCa, residing in King County, Washington, was identified for each study using 
random digit telephone dialling.  Controls were frequency-matched to cases by five-
year age groups and recruited evenly throughout each ascertainment period for 
cases.  A total of 2,448 men were identified who met the eligibility criteria and 1,645 
(67%) completed a study interview.  Blood samples were drawn and DNA prepared 
from 1,352 (82%) interviewed controls.  
 
MAYO, Rochester, Minnesota, US 
The Mayo Clinic study consisted of clinic-based cases, including 476 affected men 
from 185 families with PrCa, 445 men with sporadic PrCa, 199 with aggressive 
(Gleason score > 7) PrCa, and 500 population-based controls. The controls (all 
males) were randomly selected from a sampling frame of Olmsted County, 
Minnesota, provided by the Rochester Epidemiology Project. The methods used to 
ascertain familial and sporadic PrCa patients, as well as controls, have been 
described previously8. All individuals from the Mayo Clinic study included in this 
report were of self-reported European descent.  
 
Cancer Council Victoria Prostate Cancer Program, Melbourne  
The Cancer Council Victoria’s Prostate Cancer Program includes three studies: the 
Melbourne Collaborative Cohort Study (MCCS) and the Prostate Cancer Family 
Study (PCFS). Cases and controls (and informative families) from these studies 
have been used for several stages of this research effort, beginning with the UK and 
Melbourne stage 2 GWAS. 
The MCCS is a prospective cohort study that includes 17,154 men who were aged 
40 and 69 years when recruited between 1990 and 1994. MCCS participants are 
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regularly linked to the Victorian Cancer Registry and the Australian Cancer 
Database to ascertain incident cases (1582 by end of 2008) including men 
diagnosed in other states of Australia. A random sample of MCCS participants who 
were not diagnosed with prostate cancer during follow-up provides a control group. 
The PCFS is a population-based family series of 1428 men diagnosed with prostate 
cancer before the age of 56 years and 256 men diagnosed after the age of 55 years 
who were recruited in Victoria between 1998 and 2010. Cases were ascertained 
using the population-based Victorian Cancer Registry, and family members were 
approached after gaining the consent of each case. Altogether, 77% of cases 
agreed to participate.  
 
MEC: Multiethnic Cohort 
The Multiethnic Cohort Study is a population-based prospective cohort study that 
was initiated between 1993 and 1996 and includes subjects from various ethnic 
groups -African-Americans and Latinos primarily from California (mainly Los 
Angeles) and Native Hawaiians, Japanese-Americans, and European Americans 
primarily from Hawaii. State drivers’ license files were the primary sources used to 
identify study subjects in Hawaii and California. Additionally, in Hawaii, state voter's 
registration files were used, and, in California, Health Care Financing Administration 
(HCFA) files were used to identify additional African American men. All participants 
(n=215,251) returned a 26-page self-administered baseline questionnaire that 
obtained general demographic, medical and risk factor information. In the cohort, 
incident cancer cases are identified annually through cohort linkage to population-
based cancer Surveillance, Epidemiology, and End Results (SEER) registries in 
Hawaii and Los Angeles County as well as to the California State cancer registry. 
Information on stage and grade of disease are also obtained through the SEER 
registries. Blood sample collection in the MEC began in 1994 and targeted incident 
PrCa cases and a random sample of study participants to serve as controls for 
genetic analyses. This nested PrCa case-control study in the MEC consists of 890 
invasive PrCa cases and 895 controls. This study was approved by the Institutional 
Review Boards at the University of Southern California and at the University of 
Hawaii and informed consent was obtained from all study participants. 
 
MOFFITT: Moffitt Study, Tampa, Florida, US 
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This is a hospital-based incident study of 638 patients with primary adenocarcinoma 
of the prostate. They were recruited from 2002 to 2009 at the H. Lee Moffitt Cancer 
Centre (Tampa, FL, US) and James A. Haley Veterans Affairs Hospital (Tampa, FL, 
US). Ninety-five percent of the case subjects who were asked to participate in the 
study agreed. All cancer cases were histologically confirmed by the Department of 
Pathology at each institution. The controls consisted of 147 subjects who were 
visiting the Lifetime Cancer Screening Centre, which is affiliated with the H. Lee 
Moffitt Cancer Centre or VA hospital.  All control subjects were male and had had no 
previous diagnosis of cancer.  The control subjects were frequency matched to the 
patients by age at diagnosis (± 5 years). Eighty-three percent of the control subjects 
who were asked to participate in the study consented. Non-genetic risk factor data 
for the present study were obtained through in-person interviews with the patients 
and controls at enrolment. The questionnaire covered demographic information, 
family history of cancer (i.e., whether they have one or more first-degree family 
member with PrCa), medical history, and detailed tobacco consumption.  For the 
patients, data on cancer stage, Gleason score, and prostate specific antigen level 
were abstracted from the medical records. The subjects were asked to provide a 
blood or buccal sample after the interview as a source of genomic DNA.  
 
PCMUS: Bulgaria 
The Bulgarian sample of PrCa patients consist mainly of newly diagnosed cases, 
which are histopathologically confirmed. The patients (N=150, age range 39-93) are 
of Bulgarian origin. Transrectal biopsy was performed at the Urology Clinic, 
Alexandrovska University Hospital, mainly because of an elevated PSA. Some of the 
patients were referred from other centres to the tertiary university hospital after being 
previously diagnosed with PrCa. A small subset of patients had previously had 
definitive treatment (mainly radical prostatectomy) and they were called 
retrospectively with invitation to join the study. The control group is matched to the 
patients by sex, age, and ethnicity. It consists of two groups: (i) 72 healthy males, 
age range 54-87, presenting to our institution with lower urinary tract symptoms 
caused by benign prostatic hypertrophy (BPH) who had a PSA <3.5. The majority of 
them subsequently underwent surgical treatment with histological verification of the 
BPH; (ii) an additional healthy control group of 78 anonymous males matched to the 
PrCa patients by age and ethnicity, but with no PSA data.  
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POLAND 
Polish case-control series included 458 men with PrCa, diagnosed in north-western 
Poland between 1999 and 2009 at the University Hospital in Szczecin.  Study 
participants were unselected for age and family history. The mean age of PrCa 
diagnosis was 68 years (range 41–90 years). The control group included 476 
cancer-free adult men from the same population (age range, 24–89 years; mean 
63.1) taken from the healthy adult patients of five family doctors practicing in the 
Szczecin region. These individuals were selected randomly from the patient lists of 
the participating doctors.   
 
ProtecT/ ProMPT, UK  
The ProtecT9 (Prostate testing for cancer and Treatment) trial is an NIHR-funded, 
UK-wide study of community-based PSA testing followed by a randomised controlled 
trial of PrCa treatment (radical surgery, radical conformal radiotherapy and active 
monitoring: ProMPT).  Over 200,000 men between the ages of 50 and 69 years, 
ascertained through general practices in nine regions in the UK, were approached 
and over 100, 000 attended for PSA testing and, when PSA was 3.0ng/ml or more, 
for prostate cancer diagnosis. Over 95% of recruited men were of white ethnicity. 
For this study, after QC, 1563 cases identified by PSA screening within the ProtecT 
study were analysed. Controls with normal PSA levels (<3ng/ml) were selected from 
the same GP register and 5 year age band as the cases (n=1474 after QC were 
analysed). 
 
QUEENSLAND (QLD):  Australia 
The Queensland cases included in this study were ascertained from three studies: (i) 
a longitudinal cohort study (Prostate Cancer Supportive Care and Patient Outcomes 
Project: ProsCan) being conducted through CCQ in Queensland, through which men 
newly diagnosed with prostate cancer from 26 private practices and 8 public 
hospitals were directly referred to ProsCan at the time of diagnosis by their treating 
clinician (N=780, age range 43-88 years) (ii) Caucasian patients accrued to date 
through the Queensland node of the Australian Prostate Cancer BioResource 
(APCB) where cases were recruited through local urologists at time of diagnosis 
(N=445) (iii) Prospective collection through various urologists (N=121). All cases had 
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histopathologically confirmed prostate cancer, following presentation with an 
abnormal serum PSA and/or lower urinary tract symptoms.. Controls, recruited 
through QUT and QIMR, comprised healthy male blood donors with no personal 
history of prostate cancer, from the (i) the Australian Red Cross Blood Services in 
Brisbane (N=865, age range 19-76 years) and (ii) the Australian Electoral 
Commission (N=529, age and post-code/area matched to ProsCan, age range 54-90 
years) 
 
SEARCH 
Prostate cancer cases were identified via the Eastern Cancer Registration and 
Information Centre, East Anglia, UK. Incident cases <70 years at diagnosis are 
recruited. Controls are men attending general practice who are frequency- matched 
to cases by age and geographic region. 
 
TAMPERE:  Finland  
Total of 8744 Finnish samples were sent to for typing. Of these, 2960 unselected 
cases and 165 controls (PSA < 4 µg/ml) were collected in Tampere, Finland and all 
are of Finnish origin. The mean age of diagnosis was 68.7 years (range 36-94). The 
patients were diagnosed with PrCa in 1993-2008 in the Tampere University Hospital, 
Department of Urology. Tampere University Hospital is a regional referral centre in 
the area for all patients with PrCa, which results in an unselected, population-based 
collection of patients. The other unselected set of samples were 5522 samples 
collected in the Finnish arm of The European Randomized Study of Screening for 
Prostate Cancer, which was initiated in the early 1990s to evaluate the effect of 
screening with prostate-specific–antigen (PSA) testing on death rates from PrCa. 
This sample set includes 1106 Finnish cancer cases and 4416 controls. These men 
were born in years 1933, 1937 and 1941 and were randomly assigned to a group 
that was offered PSA screening at an average of once every 4 years or to a control 
group that did not receive such screening. In addition to these two sporadic sample 
sets, 97 familial cancer cases (mean age at diagnosis 70 years) from Finnish PrCa 
families were genotyped.   
 
UKGPCS 
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Blood DNA from PrCa cases was collected from cases throughout the UK aged < 60 
years at diagnosis and a systematic series from the PrCa clinic at The Royal 
Marsden NHS Foundation Trust.  Diagnosis is confirmed from medical record or 
death certificate.  60% are clinically detected.  
 
ULM: Germany  
Cases were recruited in two different ways. Familial PrCa probands (index cases) 
were ascertained from all over Germany. They were advised by their attending 
physicians to contact the Clinic of Urology of Ulm. The positive family history was 
then verified by reviewing medical records or death certificates of family members. In 
each case, only one member of each family (e.g. the proband) was enrolled in the 
present study. Sporadic cases, who reported no relatives affected with PrCa, were 
almost exclusively collected at Ulm during their course of treatment (e.g. radical 
prostatectomy) in our Urology Clinic. The control group consists of 213 age-matched 
healthy men and 295 population controls of unknown disease status.  
 
UTAH, US 
All 455 prostate cancer cases were drawn from the set of sampled prostate cancer 
cases belonging to extended Utah high-risk pedigrees.  All cases were selected to 
have kinship coefficients <= 0.0156 with any other case 
included from the high-risk pedigree set. The 256 controls were selected from other 
high-risk pedigree studies as: 1) not related to prostate kindred, 2) not having 
cancer, 3) not having a first degree relative with prostate cancer. 
 
SFPCS (NC-CCPC): San Francisco, California USA  
The San Francisco Bay Area Prostate Cancer Study is a population-based case-
control study of PrCa in non-Hispanic white and African-American men conducted in 
the San Francisco Bay Area (John et al 2005). Eligible cases with localized or 
advanced disease and controls completed an in-person interview; a blood or 
mouthwash sample was collected for advanced cases and controls only. Newly 
diagnosed cases aged 40-79 years  wereidentified through the Greater Bay Area 
Cancer Registry, including on-Hispanic white cases diagnosed between July 1, 1997 
and February 28, 2000, and African-American cases diagnosed between July 1, 
1997 and December 31, 2000.   Control men aged 40-79 years without a history of 
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prostate cancer were identified through random-digit dialing; Incontrols aged 65-79 
years were also randomly selected from the rosters of beneficiaries of the Health 
Care Financing Administration (HCFA). Controls were frequency-matched to cases 
by five-year age group and race. This study included 389 advanced cases and 256 
controls with DNA from a blood sample. 
Esther John, Amit Joshi, Ahva Shahabi 
 
TASPRAC: Tasmania, Australia 
The Tasmanian cases were ascertained from two studies. The fifty-four familial PrCa 
cases included in this study were drawn from the Tasmanian Familial Prostate 
Cancer Study, which has recruited families with multiple individuals affected with 
PrCa. These families were identified using the records of the Tasmanian Cancer 
Registry (a register of all cancer diagnoses in Tasmania, Australia since 1978) and 
the genealogical records from the Menzies Research Institute Tasmania 
Genealogical Database; they comprise families with at least 2 affected first-degree 
relatives.  One case per family was selected for inclusion. Blood samples, pathology 
specimens and pathology reports are available for these familial cases.  The 
remaining 469 sporadic PrCa cases were drawn from the Tasmanian Prostate 
Cancer Case Control Study. Cases were again identified from the Tasmanian 
Cancer Registry, and eligible cases were men <70 years diagnosed with 
histologically confirmed PrCa diagnosed between 1996 and 2005.  The 359 controls 
included here were randomly selected from the Tasmanian electoral roll (registration 
on the electoral roll is compulsory in Australia for individuals > 18 years).  Eligible 
controls were sex and age-matched within 5-year age groups to the sporadic cases 
and self-reported as unaffected with PrCa. Blood samples, physical measures, 
dietary history, environmental exposure data and family history have been collected 
from participating individuals.  Of note, controls diagnosed with PrCa subsequent to 
their recruitment have been removed from the control dataset. Notification of their 
subsequent diagnosis with PrCa was determined by their registration as a confirmed 
case by the Tasmanian Cancer Registry as of the end of 2009. 
Joanne L Dickinson (PI), James R. Marthick 
 
USC: Los Ángeles,  Southern California, USA 
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Subjects were participants in a population-based case-control study of aggressive 
PrCa conducted in Los Angeles County. Cases were identified through the Los 
Angeles County Cancer Surveillance Program rapid case ascertainment system 
large hospitals are screened at least weekly and other sites at least monthly.  
Eligible cases included African American, Hispanic, and non-Hispanic white men 
diagnosed with a first primary PrCa between January 1, 1999 and December 31, 
2003.  Eligible cases also had either (1) prostatectomy with documented tumour 
extension outside the prostate, (2) metastatic PrCa in sites other than prostate, (3) 
needle biopsy of the prostate with Gleason grade >8 or (4) needle biopsy with 
Gleason grade 7 and tumour in more than 2/3 of the biopsy cores.   
Eligible controls were men never diagnosed with PrCa, living in the same 
neighbourhood as a case, and were frequency matched to cases on age (±5 years) 
and race/ethnicity.  Controls were identified by a neighbourhood walk algorithm 
which proceeds through an obligatory sequence of adjacent houses or residential 
units beginning at a specific residence that has a specific geographic relationship to 
the residence where the case lived at diagnosis.  
Sue Ann Ingles, Mariana C. Stern, Roman Corral 
 
BiPAS: The Birmingham Prostatic Neoplasms Association Study (BiPAS) – A 
Genetic and Environmental Case Control Study  
The Birmingham Prostatic Neoplasms Association Study base consists of men living 
in the south Birmingham area, United Kingdom aged >50 years. The study recruited 
men with lower urinary tract symptoms (LUTS) and/or high serum prostate specific 
antigen (PSA) levels referred for prostate biopsies between March 2007 until 
October 2008. PrCa cases were recruited from the Queen Elizabeth Medical Centre, 
Birmingham. Cases are defined as men with histologically confirmed 
adenocarcinoma of the prostate. Controls were also recruited from the Queen 
Elizabeth Medical Centre and Selly Oak Hospital, Birmingham. Men with a normal 
repeat PSA and a negative biopsy were categorized as benign controls.  
A blood sample from every hospital based subject was obtained using standard 
venepuncture methods, and collected in a 5ml tube containing EDTA. Samples were 
transported to the laboratory immediately in a cool bag with cool packs and stored at 
4°C. DNA was extracted using the QIAGEN maxi blood kit. 
Mr David M A Wallace - Queen Elizabeth Medical Centre, Edgbaston, Birmingham 
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Mr Alan Doherty - Queen Elizabeth Medical Centre, Edgbaston, Birmingham 
Mr R I Bhatt - Queen Elizabeth Medical Centre, Edgbaston, Birmingham 
Mr K Subramonian - Queen Elizabeth Medical Centre, Edgbaston, Birmingham 
Dr John Arrand – University of Birmingham 
Louise Flanagan – University of Birmingham 
Sita Ann Bradley - Queen Elizabeth Medical Centre, Edgbaston, Birmingham 
 
AARHUS, Denmark 
The Aarhus Prostate Cancer Study included 661 cases and 601 controls. Cases 
were patients treated for prostate adenocarcinoma at Department of Urology, 
Aarhus University Hospital, Skejby (Aarhus, Denmark) from 1999-2008. Median age 
at diagnosis was 63 years. The vast majority of these patients (91%) were treated by 
radical prostatectomy for clinically localized PrCa, while the remaining patients (9%) 
underwent palliative treatment for disseminated disease (transurethral resection of 
the prostate and/or endocrine treatment). Controls were age-matched males treated 
for myocardial infarction or undergoing coronary angioplasty, but with no prostate 
cancer diagnosis based on information retrieved from the Danish Cancer Register 
and the Danish Cause of Death Register. For SNP genotyping analyses, genomic 
DNA was extracted from frozen blood samples using the automated MaxwellTM 16 
Instrument (Promega), according to the protocol provided by the manufacturer. 
 
VALAIS: Switzerland in collaboration with Montreal, Canada  
Between December 1, 2002 and January 31, 2007, all urologists in a relatively 
isolated alpine region of Switzerland (canton du Valais) invited their patients 
diagnosed with invasive PrCa (all stages) to participate to a research project on 
genetic factors involved in PrCa. Both parents were required to originate from the 
canton du Valais. A detailed family history on at least 3 generations was collected by 
a trained research nurse, as well as a blood sampling. A series of healthy men, 
without a self-reported family history of PrCa, originating from the same region, 
participated as controls (blood donors and elderly patients seen in private practice). 
Most of these men had regular PSA screening. This study has contributed DNA 
samples to molecular work in Montreal. For this report the genotyping was 
performed in the UK on DNA obtained from the Montreal laboratory which was 
sourced from the Valais sample set. 
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Hannover Prostate Cancer Study, Hannover, Germany (HaPCS) 
A hospital-based series of 499 unselected Caucasian patients with prostate cancer, 
who were treated with brachytherapy between October 2000 and September 2007 at 
Hannover Medical School, were enrolled for this study. All patients had biopsy-
proven adenocarcinoma of the prostate. Indication for permanent brachytherapy was 
clinically localized low-risk early prostate cancer (cT2a or less with a PSA serum 
level <10 ng/mL and a Gleason score <7) following the European Society for 
Therapeutic Radiology and Oncology/European Association of Urology/European 
Organization for Research and Treatment of Cancer recommendations. The median 
age at diagnosis was 67 y in this patient series (range, 42-82 y). For comparison, a 
series of 504 genomic DNA samples was established from ethnically matched adult 
male blood donors at Hannover Medical School in the period from 2006 to 2007. 
 
UKGPCS, ProtecT and PRACTICAL co-authorship list 
 
The UK Genetic Prostate Cancer Study Collaborators 
Listed on UKGPC website: www.icr.ac.uk/ukgpcs 
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UK Genetic Prostate Cancer Study and The Prostate Cancer Research 
Foundation Study 
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